NCT06326619 (SurvSysT) is a clinical trial of Primary tumor resection in Colorectal Cancer, sponsored by Medizinische Hochschule Brandenburg Theodor Fontane.

Who is sponsoring NCT06326619?

NCT06326619 is sponsored by Medizinische Hochschule Brandenburg Theodor Fontane.

What drugs are being tested in NCT06326619?

Interventions in NCT06326619: Primary tumor resection, Systemic Therapy.

What condition does NCT06326619 study?

NCT06326619 studies Colorectal Cancer, Neoadjuvant Systemic Therapy.

Is NCT06326619 still recruiting?

NCT06326619 is currently completed. Last updated 22 March 2024.

Last reviewed 2024-03-22 · How we verify

NCT06326619: SurvSysT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients

Completed Last updated 22 March 2024

What this trial tests

trial testing Primary tumor resection in Colorectal Cancer in 480 participants. Completed in 31 December 2020.

Timeline

1 January 2012

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Medizinische Hochschule Brandenburg Theodor Fontane
Status	Completed
Study type	OBSERVATIONAL
Enrollment	480
Start date	1 January 2012
Primary completion	31 December 2020
Estimated completion	31 December 2020

Drugs / interventions tested

Primary tumor resection
Systemic Therapy — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Neoadjuvant Systemic Therapy — all drugs for Neoadjuvant Systemic Therapy →

Sponsor

Medizinische Hochschule Brandenburg Theodor Fontane

Who can join

Eligibility, any sex, with Colorectal Cancer or Neoadjuvant Systemic Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

About 20-25 percent of all colorectal cancer patients are diagnosed with International Union Against Cancer (UICC) stage IV disease. The benefit of primary tumor resection in the palliative context is therefore of high concern. However, empirical evidence from randomized and observational studies is inconsistent. The objective of the present study is to compare the survival of palliative stage IV colorectal cancer patients selected for primary tumor resection and systemic treatment (PTR+SYST) to patients with systemic treatment only (SYST).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Patients with stage IV colorectal carcinoma selected for palliative primary tumor resection and systemic therapy survive longer compared with systemic therapy alone: a retrospective comparative cohort study.
Mantke R, Schneider C, von Ruesten A, Hauptmann M. · · 2024 · cited 2× · PMID 38935125 · DOI 10.1097/js9.0000000000001838

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Medizinische Hochschule Brandenburg Theodor Fontane trials

Trials by the same sponsor.

NCT06902337 — Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany · active not recruiting
NCT07017153 — Patient Decision Aids for Hypertension: A Pilot Study · NA · completed
NCT06575582 — Digital Navigators for Acceptance and Competence Development with Mental Health Apps · NA · recruiting
NCT06631560 — Hepatitis E Virus Infection in Oncological Patients · NA · completed
NCT03052283 — Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06326619 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medizinische Hochschule Brandenburg Theodor Fontane
Last refreshed: 22 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06326619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing